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Mitochondria are of central importance for energy generation in skeletal muscles. Expression changes or functional alterations in
mitochondrial enzymes play a key role during myogenesis, ﬁbre maturation, and various neuromuscular pathologies, as well as
natural ﬁbre aging.Massspectrometry-based proteomics suggests itself as a convenient large-scale and high-throughput approach
to catalogue the mitochondrial protein complement and determine global changes during health and disease. This paper gives a
brief overview of the relatively new ﬁeld of mitochondrial proteomics and discusses the ﬁndings from recent proteomic surveys of
mitochondrial elements in aged skeletal muscles. Changes in the abundance, biochemical activity, subcellular localization, and/or
posttranslationalmodiﬁcationsin key mitochondrialenzymes might be useful as novel biomarkers of aging. In the longterm, this
may advance diagnostic procedures, improve the monitoring of disease progression, help in the testing of side eﬀects due to new
drug regimes, and enhance our molecular understanding of age-related muscle degeneration.
1.Introduction
The neuromuscular system is severely aﬀected during the
natural agingprocess [1].Pathophysiological cyclesofdener-
vation and impaired reinnervation, the loss of entire motor
units, unloading due to prolonged periods of disuse, and
excitation-contraction uncoupling may trigger a substantial
loss in skeletal muscle mass and function [2]. Although con-
siderable interindividual diﬀerences exist in the functional
decline of the musculature during aging, most elderly people
experience a general loss in skeletal muscle strength [3].
While regular physical activity and a protein-rich diet can
partially counteract severe muscle wasting [4], a sedentary
life style and certain medical conditions, such as diabetes,
cancer, renal failure, chronic obstructive pulmonary disease,
or congestive heart failure [5–7], clearly promote muscle
degeneration [8]. Skeletal muscle wasting plays a crucial role
in physical disability, frailty, and loss of independence in
aged people [9]. Skeletal muscle wasting in the elderly has
been termed sarcopenia of old age, whereby this muscular
impairment is probably due to multiple factors [10], as out-
lined in Figure 1. On the cellular level, a variety of abnormal
structural, physiological, and biochemical processes have
been identiﬁed that are directly or indirectly associated with
age-dependentmusclewasting. Thisincludesaseveredecline
in contractile eﬃciency [11], increased apoptosis [12],
denervation-associated atrophy [13], bioenergetic changes
[14], impaired ion homeostasis [15], excitation-contraction
uncoupling [16], decreased capacity for ﬁbre regeneration
[17], a partially diminished cellular stress response [18],
and an altered equilibrium of hormones and growth factors
crucial for the maintenance of contractile function [19],
as well as oxidative stress and mitochondrial abnormalities
[20–22] .T h eg e n e r a li s s u eo fﬁ b r et y p es h i f t i n gd u r i n g
aging is still controversial. Although individual muscles
in aged humans and animal models of sarcopenia exhibit
alterations in the molecular composition ofcontractile ﬁbres
and changes in their glycolytic and aerobic capacity, ﬁndings
on distinct shifts in ﬁbre types with aging are highly variable
[23–26]. However, since mitochondrial functions are clearly
impaired in senescent muscle tissues, it was of interest to
summarize the impact of recent mass spectrometry-based
proteomic studies on the molecular fate of mitochondrial
enzymes in senescent ﬁbres. This paper brieﬂy outlines2 Journal of Aging Research
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Figure 1: Overview of the multifactorial etiology of sarcopenia.
Shown are the main physiological and biochemical events that
trigger chronic tissue wasting and severe contractile weakness in
senescent skeletal muscles. One of the most striking age-related
changes is a drastic alteration in the abundance of mitochondrial
enzymes.
the proposed role of mitochondria in cellular senescence
and recent achievements of mitochondrial proteomics and
then focuses on ﬁndings from proteomic proﬁling studies of
aged skeletal muscle preparations and the identiﬁcation of
mitochondrial elements as potential markers of ﬁbre aging.
2.Mitochondria and CellularSenescence
Mitochondria are the primary site for energy generation via
oxidative phosphorylation and play a key role in protein
transport, intermediary metabolism, cell cycle progression,
calcium signaling, and the regulation of apoptosis [27].
Proteomic cataloguing studies of this crucial organelle
suggest the existence of approximately 1,500 mitochondrial
proteins [28–30], whereby altered expression levels within
the mitochondrial proteome are critical factors for normal
development and numerous diseases [31–33]. Changes in
mitochondria have long been associated with playing an
integral role during natural aging [34–37], and the phar-
macological application of antioxidants for counteracting
mitochondria-speciﬁc symptoms of senescence is being
extensively studied [38]. Interestingly, the mitochondrial
theory of aging also encompasses the mechanisms that may
lead to cellular senescence in contractile tissues [39–41].
Alteredlevelsofmitochondrial activityinagedmuscletissues
have been well established and extensively reviewed [42–
44]. The detrimental accumulation of mitochondrial DNA
deletions and mutations on the genetic level and deﬁcien-
cies in the mitochondrial electron transport chain on the
biochemical level are clearly associated with muscle aging.
The pathological consequences of an age-related decline in
mitochondrial function are the impairment of essential ATP-
dependent cellular processes [45] and ampliﬁed oxidative
stress in senescent tissues due to the increased release of
reactive oxygen species from the mitochondrial respira-
tory chain [46, 47]. In general, senescent muscle tissues
are exposed to an enhanced production of mitochondrial
reactive oxygen species, increased mitochondrial apoptotic
susceptibility, disturbed mitochondrial bioenergetic func-
tions, and a reduced transcriptional drive for mitochondrial
biogenesis [22, 48]. Although these functional impairments
clearly occur in skeletal muscle mitochondria during aging,
biochemical studies have also demonstrated considerable
age-related changes in the abundance and posttranslational
modiﬁcations of key mitochondrial enzymes.
3.Proﬁlingof theMitochondrial Proteome
Proteomics is concerned with the large-scale and high-
throughput identiﬁcation and characterization of the global
protein constellation of a given biological entity, such as
cells, tissues, or body ﬂuids [49]. Protein complements are
separated bystandard methods, includinggelelectrophoresis
and liquid chromatography [50–52], and individual pro-
tein species are usually identiﬁed by mass spectrometry
[53–55]. The veriﬁcation of proteomic data is routinely
carried out by biochemical, immunological, cell biological,
and physiological assays. Skeletal muscle proteomics, in
particular, involves the comprehensive biochemical anal-
ysis of protein populations from deﬁned muscle tissues,
individual muscles, speciﬁc ﬁbre populations, or distinct
subcellular fractions [56–58]. Figure 2 outlines the standard
workﬂow for the identiﬁcation of novel aging-associated
biomarkersusinggelelectrophoresis-based proteomics.Total
crude tissue extracts, detergent phase-extracted proteins,
or mitochondria-enriched fractions are routinely used as
starting material forthedetermination ofnew mitochondrial
markers. The main analytical steps involved in skeletal
muscle proteomics are the extraction of a distinct protein
population from crude extracts, subcellular fractions, or
aﬃnity-puriﬁed protein complexes, the eﬃcient separation
of proteins by one-dimensional gel electrophoresis, two-
dimensional gel electrophoresis, or liquid chromatography,
the densitometric mapping of altered protein concentration
levels, the unequivocal identiﬁcation of protein species by
mass spectrometry of protease-generated peptide mixtures,
and ﬁnally the independent validation of proteomic data by
enzyme assays, immunoblot analysis, ligand binding assays,
or immunoﬂuorescence microscopy.
Since the concentration range of proteins is not a static
entity, but highly dynamic, and because the density of
proteins spans several orders of magnitude in complex
cellular systems, proteomic studies of crude extracts resultJournal of Aging Research 3
mostly in the cataloguing of abundant and soluble protein
species. Thus, conventional gel electrophoresis-based pro-
teomics underestimates certain classes of proteins, such as
high-molecular-mass proteins, integral membrane proteins,
extremely basic or acid proteins, and low-abundance pro-
teins [50–52]. Over the last few years, proteomic approaches
have been reﬁned in order to reduce sample complexity by
subcellular fractionation protocols and aﬃnity separation
techniques [59–61]. Mass spectrometry-based proteomics
suggests itself as an ideal analytical method to determine
global changes in the mitochondrial protein complement
[62, 63]. Mitochondrial proteomics is concerned with the
establishment of the entire organelle-associated protein
complement and the dynamic nature of posttranslational
modiﬁcations in mitochondrial components, as well as
diﬀerentialexpressionpatternswithinmitochondrialprotein
populations due to physiological adaptations or pathological
insults [64–66]. Considerable tissue-speciﬁc diﬀerences exist
within the mitochondrial proteome and reﬂect the diversity
of mitochondrial functions in individual organs [67–69]. As
listed in Table 1, proteomic maps of mitochondria exist for
numerous organs from several diﬀerent species.
The ﬁrst comprehensive survey of human mitochon-
dria detected approximately 1,500 spots on a silver-stained
reference map and identiﬁed 46 mitochondria-associated
proteins in placental tissue [70]. Subsequent studies have
discovered several hundred mitochondrial proteins by mass
spectrometry, using diﬀerential centrifugation or density
gradients consisting of percoll, metrizamide or nycodenz
for prefractionation purposes [71–77]. Proteomic analyses
yielded 615, 680 and 940 distinct mitochondrial proteins in
human and mouse heart, respectively [71–73], 182 and 192
mitochondrial proteins in mouse and rat liver, respectively
[74, 75], 823 mitochondrial proteins in human skeletal
muscle [76], and 723 and 1,198 mitochondrial proteins in
brown and white fat cell lines, respectively [77]. Several
proteomic studies have investigated mitochondrial protein
populations in several organ systems in parallel, including
liver, muscle, heart, kidney, and brain [67–69]. The most
comprehensive comparative report on the mitochondrial
proteomehascreatedacompendiumof1,098genesandtheir
protein expression across 14 mouse tissues [78]. Detailed
listings of proteomic studies that have focused on mitochon-
dria in health and disease can be found in recent extensive
reviewsofthisspecialized ﬁeld ofsubproteomics[28,30,65].
These crucial cataloguing exercises form now the basis of
detailed comparative investigations into disease-dependent
alterations in mitochondria [64], including studying the
eﬀects of aging on the mitochondrial proteome [79, 80].
4.Mitochondrial Markersof
SkeletalMuscleAging
Over the last decade, a large number of proteomic stud-
ies have identiﬁed potential biomarkers of muscle aging
[81]. Studies of aged human muscle and the most widely
employedanimal model ofsarcopenia-related abnormalities,
the senescent rat [82], have revealed changes in proteins
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Figure 2: Flowchart of the proteomic workﬂow to identify and
characterize novel mitochondrial markers involved in sarcopenia
of old age. Shown are the various steps involved in the high-
throughput proteomic screening of tissue specimens, including
sample preparation, gel electrophoretic separation, densitometric
analysis, and mass spectrometric identiﬁcation of new candidate
proteins.
involved in the regulation of excitation-contraction cou-
pling, ion homeostasis, muscle contraction, muscle relax-
ation, metabolite transportation, energy metabolism, and
the cellular stress response [83–99]. Table 2 lists recent pro-
teomic studies that have identiﬁed the potential involvement
of mitochondrial elements in sarcopenia of old age. The
proteomic analysis of total extracts from aged human vastus
lateralis muscle has identiﬁed numerous aerobic markers
with an increased density, including the mitochondrial
enzymes ATP synthase, ubiquinol-cytochrome c reductase,
and oxoglutarate dehydrogenase during muscle aging [86].
In analogy, elevated levels of mitochondrial enzymes, such
as succinate dehydrogenase, isocitrate dehydrogenase, ATP
synthase, malate dehydrogenase, ubiquinol-cytochrome c
reductase, and pyruvate dehydrogenase, were also shown
to occur during the aging of rat gastrocnemius muscle
[93, 94]. These investigations were performed with the
ﬂuorescence diﬀerence in-gel electrophoretic technique, one
of the most powerful biochemical methods to compare4 Journal of Aging Research
Table 1: List of major proﬁling studies of the mitochondrial proteome.
Proteomic studies Mitochondrial protein identiﬁcation Reference
Proteomic analysis of
human placenta
First comprehensive cataloguing of the mitochondrial proteome, which
resulted in the identiﬁcation of 46 distinct proteins
Rabilloud et al. [70]
Analysis of human and
mouse heart
Identiﬁcation of 680 human mitochondrial proteins and 940 mouse
mitochondrial proteins in heart muscle
Taylor et al. [71],
Gaucher et al. [72],
Zhang et al. [73]
Proteomic proﬁling of
mouse and rat liver
Identiﬁcation of 182 mouse proteins and 192 rat proteins that are associated
with liver mitochondria
da Cruz et al. [74],
Fountoulakis et al. [75]
Proteomic proﬁling of
human skeletal muscle
Identiﬁcation of 823 mitochondrial proteins in human vastus lateralis
muscle Lefort et al. [76]
Proteomic proﬁling of
brown and white adipose
cell lines
Identiﬁcation of 723 mitochondrial proteins in brown adipose cell line and
1,198 mitochondrial proteins in white adipose cell line Forner et al. [77]
Comparative studies for the
establishment of the
mammalianmitochondrial
proteome from various
tissues
Identiﬁcation of tissue-speciﬁc expression patterns of mouse and rat
mitochondrial proteins from liver, skeletal muscle, kidney, brain, heart, and
various other organs. The most comprehensive comparative study
established the mitochondrial protein complement in 14 diﬀerent tissues
Mootha et al. [67],
Forner et al. [68],
Reifschneider et al. [69],
Pagliarini et al. [78]
concentration changes of distinct protein species in sol-
uble proteomes [100]. The recent proteomic proﬁling of
the detergent phase-extracted protein complement from
senescent rat gastrocnemius muscle conﬁrmed a changed
concentration of numerous mitochondrial enzymes during
aging. The mitochondrial marker enzymes ATP synthase
and isocitrate dehydrogenase were found to be signiﬁcantly
increased in agedmuscletissue [99]. Incontrast to thehighly
discriminatory diﬀerence in-gel electrophoretic technique
used for studying muscle aging [86, 93, 94, 97], proteomic
approaches with conventionalprotein dyes ordyesthat cover
a limited dynamic range have identiﬁed considerably fewer
changes in mitochondrial markers [85, 87].
Subproteomic studies of mitochondria-enriched frac-
tions from aged skeletal muscles have shown diﬀerential
eﬀects on the abundance of mitochondrial enzymes [90,
91, 96–98]. Chang et al. [90] have studied the eﬀect of
aging and caloric restriction on the rat mitochondrial
proteome. In skeletal muscles, isocitrate dehydrogenase and
malate dehydrogenase were shown to be increased in 25-
month-old Fisher 344 rats, as compared to 6-month-old
rats. Caloric restriction appears to have only a minor
eﬀect on age-related changes in the mitochondrial protein
complement [90]. Severe metabolic changes in aged skeletal
muscle were conﬁrmed by an extensive proteomic survey
of mitochondrial preparations from 3-month-old versus 26-
month-old rat gastrocnemius muscles [97]. These muscle
specimens represent youngadult versussenescentcontractile
tissues, respectively. The ﬂuorescent diﬀerence in-gel elec-
trophoretic analysis demonstrated an age-dependent eleva-
tion in numerous mitochondrial proteins, including NADH
dehydrogenase, ATPase synthase, succinate dehydrogenase,
the mitochondrial inner membrane protein mitoﬁlin, per-
oxiredoxin isoform PRX-III, mitochondrial ﬁssion protein
Fis1, succinate-coenzyme A ligase, acyl-coenzyme A dehy-
drogenase, ubiquinol-cytochrome c reductase core I protein,
prohibitin, and porin isoform VDAC2 (Figure 3).
Proteomic studies of posttranslational changes in aged
skeletal muscle have revealed increased nitration levels in
succinate dehydrogenase [83], decreased phosphorylation
levelsincytochromecoxidaseandaconitase[92],andaltered
carbonylation levelsin ATP synthase, NADHdehydrogenase,
pyruvate dehydrogenase, and isocitrate dehydrogenase [91]
during muscle aging [101]. Abnormal posttranslational
modiﬁcations may alter protein stability, subcellular tar-
geting, intra- and intermolecular interactions, as well as
coupling eﬃciency between substrates and active sites in
aﬀectedmitochondrial enzymes. This might partially explain
impaired mitochondrial functioning in senescent ﬁbres.
Thus, natural aging of skeletal muscles appears to be associ-
ated with distinct changes in posttranslational modiﬁcations
ofimportant mitochondrial enzymes. Recently,Ferreiraetal.
[102] compared the proteomes of subsarcolemmal versus
intermyoﬁbrillar mitochondria from rat skeletal muscle.
Ad i ﬀerential expression pattern was established for 38
mitochondrial proteins. In the future, reﬁned proteomic
studies might be able to determine whether intermyoﬁbrillar
mitochondria are diﬀerently aﬀected by muscle aging as
compared to subsarcolemmal mitochondria.
5.Conclusion
Since improved nutritional intake and exercise intervention
can onlypartially alleviate the symptoms of sarcopenia, there
is an urgent need to develop novel pharmacological strate-
gies to prevent age-related muscle wasting [103]. Recent
publications by working groups on the etiology, epidemiol-
ogy, potential interventions, and the clinical assessment of
sarcopenia show that a general deﬁnition of this common
geriatric syndrome is still evolving [104–109]. In the future,
it will be crucial to establish reliable sarcopenia-speciﬁc
biomarkers to develop superior diagnostic tools for the
correct classiﬁcation ofthisage-dependentmusclepathology
[110]. Mass spectrometry-based proteomics suggests itselfJournal of Aging Research 5
Table 2: Proteomic identiﬁcation of mitochondrial proteins during skeletal muscle aging.
Proteomic study Changes in mitochondrial marker proteins Reference
Analysis of total extracts
from aged humanvastus
lateralis muscle
General increase in aerobic markers, including mitochondrial enzymes such
as ATP synthase, ubiquinol-cytochrome c reductase, and oxoglutarate
dehydrogenase during muscle aging
Gelﬁ et al. [86]
Analysis of total extracts
from rat gastrocnemius
muscle
Increase in mitochondrial enzymes, such as succinate dehydrogenase,
isocitrate dehydrogenase, ATP synthase, and malate dehydrogenase during
muscle aging
Doran et al. [93]
Analysis of total extracts
from rat gastrocnemius
muscle
Diﬀerential eﬀect on the abundance of mitochondrial isoformsof aconitase
during muscle aging
O’Connell et al. [87]
Analysis of total extracts
from aged rat
gastrocnemius muscle
Moderate eﬀect on cytochrome c oxidase and isocitrate dehydrogenase
during muscle aging
Piec et al. [85]
Analysis of total extracts
from rat gastrocnemius
muscle
Increase in many enzymes involved in oxidative metabolism, such as ATP
synthase, isocitrate dehydrogenase, ubiquinol-cytochrome c reductase, and
pyruvate dehydrogenase during muscle aging
Capitanio et al. [94]
Subproteomic study of the
eﬀect of aging and caloric
restriction on rat muscle
mitochondria
Increased levels of isocitrate dehydrogenase and malate dehydrogenase in
aged muscle mitochondria. Caloric restriction appears to have only a
marginal eﬀect on the mitochondrial proteome
Chang et al. [90]
Subproteomic analysis of
mitochondria-enriched
fraction from aged rat
gastrocnemius muscle
Increased levels of mitochondrial creatine kinase, NADH dehydrogenase,
ATP synthase, succinate dehydrogenase, and ubiquinol cytochrome c
reductase during muscle aging
O’Connell and
Ohlendieck [97]
Analysis of total extracts
and mitochondria-enriched
fraction from aged
ratgastrocnemius muscle
Diﬀerential eﬀect on mitochondrial enzymes, such as pyruvate
dehyrdogenase, cytochrome c oxidase, isocitrate dehydrogenase, and ATP
synthase during muscle aging
Lombardi et al. [96]
Subproteomic analysis of
mitochondria-enriched
fraction from aged mouse
hind limb muscles
Diﬀerential eﬀects on the abundance and carbonylation of various
mitochondrial enzymes, including NADH dehydrogenase, cytochrome c
oxidase, and ATP synthase during muscle aging
Alves et al. [98]
Analysis of detergent
phase-extracted protein
complement from aged rat
gastrocnemius muscle
Increase in mitochondrial marker enzymes, such as ATP synthase and
isocitrate dehydrogenase during muscle aging
Donoghue et al. [99]
Proteomic analysis of
n i t r a t i o ni na g e dr a t
skeletal muscle
Increased nitration levels in succinate dehydrogenase Kanski et al. [84]
Phosphoproteomic analysis
of total extracts from aged
rat gastrocnemius muscle
Decreased phosphorylation levels in cytochrome c oxidase and aconitase
during muscle aging
Gannon et al. [92]
Proteomic analysis of
c a r b o n y l a t i o ni na g e dr a t
skeletal muscle
mitochondria
Altered carbonylation levels in numerous mitochondrial proteins, including
ATP synthase, NADH dehydrogenase, pyruvate dehydrogenase, and
isocitrate dehydrogenase during muscle aging
Feng et al. [91]
as an ideal analytical tool for the study of skeletal muscle
aging. The biochemical establishment of a robust protein
marker signature for sarcopenia of old age will be extremely
useful for (i) formulating a coherent cellular theory of
muscle aging, (ii) the development of proper diagnostic
criteria that can diﬀerentiate between diﬀerent degrees
of age-related muscle weakness, (iii) the identiﬁcation of
novel therapeutic targets to counteract cellular stress and
ﬁbre degeneration during aging, and (iv) the evaluation of
improved treatment regimes to slow down the aging process.
Recent proteomic studies of mitochondria-enriched frac-
tions and total skeletal muscle extracts have demonstrated
altered levels of key mitochondrial enzymes in senescent
muscle tissues. Aged neuromuscular systems appear to
contain a higher degree of certain mitochondrial enzymes.
Thus, although mitochondrial dysfunction and oxidative
stress are associated with sarcopenia, muscle aging is also
clearly linked to metabolic alterations. This suggests that
abundant mitochondrial enzymes may be useful for general
muscle proﬁling and are excellent biomarker candidates for6 Journal of Aging Research
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Figure 3: Proteomic proﬁling of the mitochondria-enriched fraction from aged skeletal muscle tissue. Shown is the comparative graphic
representation of distinct two-dimensional protein spots with a changed expression in aged muscle as judged by ﬂuorescence diﬀerence
in-gel electrophoretic analysis [97]. Individual panels document alterations in the abundance of NADH dehydrogenase (NADH-DH), the
inner mitochondrial membrane protein mitoﬁlin, prohibitin, the porin isoform VDAC 2, succinate dehydrogenase (SDH), acyl-coenzyme
A dehydrogenase (Acyl-CoA-DH), peroxiredoxin isoform PRX-III, ubiquinol-cytochrome c reductase core I protein (Ubq-Cytc-RED),
succinate-coenzyme A (Suc-CoA) ligase, and mitochondrial F1-ATPase.
the biochemical classiﬁcation of cellular changes during the
natural aging process.
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